October 2, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 
Suprema Provides Palm-print Live Scanners to Poland & Lithuania
Suprema Provides Palm-print Live Scanners to Poland & Lithuania
Seoul, Nov 23, 2010 - (ACN Newswire) - Suprema, Inc., a global leader in biometrics and ID solutions, announced today that the company's RealScan-F palm-print live scanner has been selected for the AFIS systems of the Polish National Police and Lithuania's Citizenship & Migration Affairs.   [ more... ]

 Headline News

Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Mitsui & Co. has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). more info >>
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Yokogawa Electric announced that its confocal image single-cell drug discovery support system has been selected for the Japan Science and Technology Agency's (JST) next-generation technology transfer program (NexTEP). more info >>
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Sysmex Corporation and Toppan Printing Co., Ltd. are to cooperate for the advancement in the genetic analysis testing industry, and to invest in RIKEN GENESIS Co., Ltd., a Toppan Printing subsidiary. more info >>
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Takara Bio Inc. has submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) dated April 30, 2014 in order to conduct a phase II clinical trial in the United States of the oncolytic virus HF10 in patients with unresected or metastatic malignant melanoma. more info >>
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Nitto Denko Corporation has been developing a new RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration with Prof. Yoshiro Niitsu of Sapporo Medical University. more info >>
ACN Newswire
 Press Release News

Eisai Launches Anti-Cancer Agent Halaven in Australia (Oct 1, 2014)
Eisai Co., Ltd. announced today that its Australian pharmaceutical sales subsidiary Eisai Australia Pty. Ltd. (Eisai Australia) has launched Halaven (eribulin mesylate) in the country. The product is the first to be marketed exclusively by Eisai in Australia. more info >>
Phase III Trial of Aricept in Patients with Severe Alzheimer's Disease in China Meets Primary Endpoint (Sept 30, 2014)
Eisai Co., Ltd. announced today that a Phase III clinical trial (Study 339) conducted in China of Aricept (donepezil hydrochloride) in patients with severe Alzheimer's Disease (AD) met its primary endpoint. more info >>
Aricept Approved In Japan As Treatment For Dementia With Lewy Bodies (Sept 19, 2014)
Eisai Co., Ltd. announced today that its anti-Alzheimer's agent Aricept (donepezil hydrochloride) has received approval for a new indication for dementia with Lewy bodies (DLB) in Japan. more info >>
Plasmacluster Ion Technology Reduced Airway Inflammation in Pediatric Patients with Mild to Moderate Atopic Asthma (Sept 18, 2014)
In investigator initiated clinical research(5) commissioned by Sharp, results were obtained in exploratory analysis(6) indicating that Plasmacluster Ion technology reduced the level of airway inflammation in pediatric patients with mild to moderate atopic asthma (FeNO(7) value less than 90). more info >>
Eisai to Present Latest Clinical Data on Halaven(R) (Eribulin) and Lenvatinib at 39th ESMO Congress (Sept 17, 2014)
Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Halaven(R) and lenvatinib mesylate will be presented during the 39th European Society for Medical Oncology (ESMO) Congress 2014, taking place in Madrid, Spain, from September 26 - 30. more info >>
 Global Press Release

Eisai Launches Anti-Cancer Agent Halaven in Australia (Oct 1, 2014)

Phase III Trial of Aricept in Patients with Severe Alzheimer's Disease in China Meets Primary Endpoint (Sept 30, 2014)

Siloam Hospitals Again Awarded Indonesian Healthcare Services Provider of the Year by Frost & Sullivan (Sept 30, 2014)

Protecting the Body from Itself (Sept 26, 2014)

Aricept Approved In Japan As Treatment For Dementia With Lewy Bodies (Sept 19, 2014)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)